WO1991002805A3 - Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles - Google Patents

Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles Download PDF

Info

Publication number
WO1991002805A3
WO1991002805A3 PCT/US1990/004652 US9004652W WO9102805A3 WO 1991002805 A3 WO1991002805 A3 WO 1991002805A3 US 9004652 W US9004652 W US 9004652W WO 9102805 A3 WO9102805 A3 WO 9102805A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant retroviruses
inhibiting
disclosed
target cells
vector constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/004652
Other languages
English (en)
Other versions
WO1991002805A2 (fr
Inventor
Harry E Gruber
Douglas J Jolly
James G Respess
Paul K Laikind
Stephen M W Chang
Sunil D Chada
John F Warner
Jack R Barber
Louis Daniel C St
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Priority to AU61853/90A priority Critical patent/AU648261B2/en
Priority to CA002066053A priority patent/CA2066053C/fr
Publication of WO1991002805A2 publication Critical patent/WO1991002805A2/fr
Publication of WO1991002805A3 publication Critical patent/WO1991002805A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)

Abstract

Rétrovirus de recombinaison portant une construction d'un vecteur pouvant prévenir, inhiber, stabiliser ou inverser des maladies cancéreuses ou auto-immunes. Plus particulièrement, les rétrovirus de recombinaison de la présente invention sont utiles pour (a) stimuler une réponse immune spécifique envers un antigène ou un antigène pathogénique; (b) inhiber une fonction d'un agent pathogénique tel qu'un virus; et (c) inhiber l'interaction d'un agent avec un récepteur de cellule hôte. De plus, des cellules eucaryotiques infectées et des compositions pharmaceutiques contenant ce rétrovirus de recombinaison sont décrites. Divers procédés de production des rétrovirus de recombinaison ayant des caractéristiques uniques, et des procédés de production d'animaux ou insectes transgéniques sont également décrits.
PCT/US1990/004652 1989-08-18 1990-08-17 Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles Ceased WO1991002805A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU61853/90A AU648261B2 (en) 1989-08-18 1990-08-17 Recombinant retroviruses delivering vector constructs to target cells
CA002066053A CA2066053C (fr) 1989-08-18 1990-08-17 Retrovirus recombinants livrant des constructeurs de vecteur aux cellules cibles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39593289A 1989-08-18 1989-08-18
US395,932 1989-08-18
US56560690A 1990-08-10 1990-08-10
US565,606 1990-08-10

Publications (2)

Publication Number Publication Date
WO1991002805A2 WO1991002805A2 (fr) 1991-03-07
WO1991002805A3 true WO1991002805A3 (fr) 1991-04-18

Family

ID=27015310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004652 Ceased WO1991002805A2 (fr) 1989-08-18 1990-08-17 Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Country Status (5)

Country Link
EP (4) EP0845537A1 (fr)
JP (2) JP4041535B2 (fr)
AU (3) AU648261B2 (fr)
CA (1) CA2066053C (fr)
WO (1) WO1991002805A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US9133524B2 (en) 2010-07-01 2015-09-15 The Regents Of The University Of California Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
US11396551B2 (en) 2018-02-01 2022-07-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US12291567B2 (en) 2018-10-15 2025-05-06 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
JP2752788B2 (ja) * 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6555108B1 (en) * 1990-09-14 2003-04-29 The General Hospital Corporation Implanting HSV-TK retrovirus producing cells to treat tumors
US6537541B1 (en) * 1990-09-14 2003-03-25 The General Hospital Corporation Implantation of HSV-TK retrovirus producer cells to destroy glioma
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
EP1285967A3 (fr) * 1990-09-21 2005-03-02 Chiron Corporation Lignée cellulaire humaine pour l'empaquetage des rétrovirus
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
JPH07500490A (ja) * 1991-05-15 1995-01-19 ランスティチュ　ドュ　レシェルシュ　クリニーク　ドュ　モントリオール 非感染性ｈｉｖゲノムを保持するトランスジェニック非ヒト動物
US6268211B1 (en) 1991-08-20 2001-07-31 L'institut De Recherches Cliniques De Montreal Non-infectious HIV transgene
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
JPH07505773A (ja) * 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
EP0746625B1 (fr) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Particules vectorielles pouvant etre ciblees
BE1006437A3 (fr) * 1992-12-10 1994-08-30 Company S A Z Sequence nucleotidique destinee au traitement du cancer et des infections.
JPH06261764A (ja) * 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
WO1995006718A2 (fr) * 1993-09-03 1995-03-09 Viagene, Inc. Procede de suppression de la reponse auto-immune
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0729511A1 (fr) 1993-11-18 1996-09-04 Chiron Corporation Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1995033842A1 (fr) * 1994-06-07 1995-12-14 Immunomedics, Inc. Vecteurs retroviraux sans danger, leur production et utilisation
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
JP3907698B2 (ja) * 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
WO1996020731A1 (fr) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Administration directe en plusieurs sites de vehicules distributeurs de genes
JPH11505128A (ja) * 1995-05-22 1999-05-18 カイロン コーポレイション キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
WO1998000541A2 (fr) * 1996-07-03 1998-01-08 Chiron Corporation Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
WO2000000600A2 (fr) * 1997-09-22 2000-01-06 Chang Lung Ji Vecteurs lentiviraux
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
EP1030927A1 (fr) * 1997-11-12 2000-08-30 Valentis Inc. Plasmides d'expression utilises dans des vaccins a base d'acide nucleique a plusieurs epitopes
CA2316397A1 (fr) 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010041992A (ko) 1998-03-18 2001-05-25 길리스 스티브 폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
EP2261352A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
CZ20003934A3 (cs) * 1998-05-01 2001-09-12 Schering-Plough Ltd. Rekombinantní virus exprimující cizí DNA kódující kočičí CD80, kočičí CTLA-4 nebo kočičí CD-86 a jeho použití
AU4207899A (en) * 1998-05-26 1999-12-13 University Of Florida Lentiviral vector compositions and methods of use
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
EP2058334B1 (fr) * 1998-06-12 2012-10-31 Genentech, Inc. Anticorps monoclonaux, anticorps à réaction croisée et procédé de production
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69933044T3 (de) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2000039302A2 (fr) 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
YU72901A (sh) 1999-04-02 2004-07-15 Corixa Corporation Preparati za primenu u terapiji i dijagnozi raka pluća
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
JP2003500061A (ja) * 1999-05-21 2003-01-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 改善されたレトロウイルスの産生
EP1196609A2 (fr) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Memapsine recombinante catalytiquement active et procedes d'utilisation
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
WO2001036640A2 (fr) 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
CZ303468B6 (cs) 2000-02-23 2012-10-03 Smithkline Beecham Biologicals S. A. Imunogenní smes a farmaceutická smes
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
EP2000144A1 (fr) 2000-05-19 2008-12-10 Corixa Corporation Traitement prophylactique et thérapeutique des maladies infectieuses et autres avec composés à base de mono et di-saccharide
EP1950297A2 (fr) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20060141455A1 (en) 2002-01-08 2006-06-29 Rhonda Hansen Gene products differentially expressed in cancerous breast cells and their methods of use
ATE397094T1 (de) 2000-06-15 2008-06-15 Novartis Vaccines & Diagnostic Polynukleotide zur bestimmung von kolonkrebs
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
AU2002218218A1 (en) * 2000-10-10 2002-04-22 Austrian Nordic Biotherapeutics Ag A novel system for the evaluation of the activity and/or specificity of a viral component
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
WO2002079482A2 (fr) * 2000-11-16 2002-10-10 Rigel Pharmaceuticals, Inc. Genomes retroviraux in vitro, leurs procedes de fabrication et d'utilisation
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
US7127357B1 (en) 2000-12-08 2006-10-24 The Salk Institute For Biological Studies Crystal structure of WW domains and methods of use thereof
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
WO2002089747A2 (fr) 2001-05-09 2002-11-14 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003065973A2 (fr) 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Compositions de vaccins multivalents a base de streptocoques et procedes d'utilisation
CA2465953A1 (fr) 2001-11-09 2003-05-15 Georgetown University Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
CA2860702C (fr) 2001-12-17 2019-02-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
NZ535754A (en) 2002-03-15 2007-01-26 Wyeth Corp Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
EP1501855A4 (fr) 2002-03-21 2006-02-22 Sagres Discovery Inc Nouvelles compositions et nouveaux procedes pour le cancer
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
ES2627445T3 (es) 2002-05-01 2017-07-28 Miltenyi Biotec Technology, Inc. Partículas de vector de lentivirus resistentes a la inactivación por el complemento
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
DK1523582T3 (da) 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
KR101159519B1 (ko) * 2002-11-19 2012-06-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｒｒｅ 및 ｃｔｅ를 포함하는 유전자 작제물 및 조성물 및이의 용도
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CA2512108C (fr) 2003-01-06 2013-04-02 Corixa Corporation Composes d'aminoalkyle glucosaminide phosphate et leur utilisation
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1592708A2 (fr) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
EP2191846A1 (fr) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Methode de traitement de la douleur consistant a administrer un antagoniste du facteur de croissance neuronale ainsi que des medicaments anti-inflammatoires non steroidiens (nsaid) et composition les contenant
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
WO2005007673A2 (fr) 2003-07-03 2005-01-27 Rush University Medical Center Peptides immunogenes
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
TR201808440T4 (tr) 2004-07-09 2018-07-23 Henry M Jackson Found Advancement Military Medicine Inc Hendra ve nipah virüsü G glikoproteininin çözünebilen formları.
EP2848942B1 (fr) 2004-07-14 2017-03-08 The Regents of The University of California Biomarqueurs pour la détection précoce du cancer des ovaires
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO2006020684A2 (fr) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Procedes pour reguler la differenciation et traiter le myelome multiple
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
WO2006081629A1 (fr) * 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Vecteurs adenoviraux comprenant un acide nucleique codant pour une molecule mhc de classe i et utilisation de tels vecteurs dans la therapie du cancer.
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
EP1701165A1 (fr) 2005-03-07 2006-09-13 Johannes Dr. Coy Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
EP2386314A1 (fr) 2005-03-31 2011-11-16 GlaxoSmithKline Biologicals SA Vaccins contre l'infection à chlamydia
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (fr) 2005-04-07 2008-01-02 Chiron Corporation Génes liés au cancer (prlr)
EP2426141B1 (fr) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Méthode de prévention ou de traitement d'une infection par M tuberculosis
EP1907425B1 (fr) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anticorps anti-cd26 et methodes d'utilisation de ces derniers
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2636424A1 (fr) 2006-01-09 2007-10-25 The Regents Of The University Of California Combinaisons immunostimulantes de tnfrsf, tlr, nlr, rhr, recepteurs purinergiques et d'agonistes des recepteurs de cytokines pour vaccins et immunotherapie contre les tumeurs
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
EP1988920A1 (fr) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Procédés de traitement de l'obésité par administration d'un antagoniste trkb
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
EP2010226B1 (fr) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine
KR101496433B1 (ko) 2006-06-07 2015-02-26 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
WO2008020330A2 (fr) 2006-08-16 2008-02-21 Novartis Ag Immunogènes pour escherichia coli uropathogène
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
WO2009073186A1 (fr) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt
EP2139447A2 (fr) 2007-03-20 2010-01-06 Harold Brem Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
WO2008124176A2 (fr) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2570559C2 (ru) 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
EP2274437B1 (fr) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions et procédés pour la détection des mutations d'egfr en cas de cancer
EP2365003A1 (fr) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
WO2010022225A1 (fr) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Vaccins d'accostage et de verrouillage « dock-and-lock » (dnl) pour une thérapie contre le cancer
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
CA2754618A1 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigenes de chlamydia
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
WO2011004263A2 (fr) 2009-07-07 2011-01-13 Novartis Ag Immunogènes d' escherichia coli conservés
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AU2011207348A1 (en) 2010-01-21 2012-08-02 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
SI2528621T1 (sl) 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
EP2536747B1 (fr) 2010-02-19 2017-09-27 Université de Liège Un polynucleotide pour l'utilisation dans les traitements de maldies induites par des virus influenza a virus, codant pour une proteine modifiee, cette proteine modifiee et un animal transgénique exprimant un gène codant pour cette protéine modifiée
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
EP2598126A2 (fr) 2010-07-30 2013-06-05 Saint Louis University Méthodes de traitement de la douleur
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
EP2663868A2 (fr) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Procédés et compositions destinés à cibler des sites de croissance néovasculaire
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
WO2012141984A1 (fr) 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
CA2837651A1 (fr) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et methodes pour la therapie et le diagnostic du cancer
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (fr) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions et procédés pour traiter le cancer
JP6078067B2 (ja) 2011-08-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用
WO2013039996A1 (fr) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induction et activité de tissu adipeux brun à l'aide de fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
HK1204328A1 (en) 2011-12-22 2015-11-13 瑞纳神经科学公司 Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
KR20150013232A (ko) 2012-05-07 2015-02-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2014031178A1 (fr) 2012-08-24 2014-02-27 Etubics Corporation Vecteur adénoviral à réplication déficiente, utile en vaccination
HK1216428A1 (zh) 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
ES2703341T3 (es) 2013-03-14 2019-03-08 Genvivo Inc Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica
BR112015023500B1 (pt) 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
WO2014152232A2 (fr) 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicréine plasmatique
WO2014144844A1 (fr) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Petits arn dérivés d'arnt (arnts) impliqués dans la viabilité cellulaire
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
MX2015015339A (es) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3016660B1 (fr) 2013-07-01 2020-06-10 The Research Foundation for the State University of New York Inhibition de ship dans le cadre de la lutte contre l'obésité
US10711275B2 (en) 2013-07-12 2020-07-14 Zhen Huang Methods and compositions for interference with DNA polymerase and DNA synthesis
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
MX388027B (es) 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CA2944903A1 (fr) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogenes predictifs de reponse a un inhibiteur de point de controle anti-immunitaire
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CA2947605A1 (fr) 2014-05-13 2015-11-19 Bioatla, Llc Proteines biologiques conditionnellement actives
AU2015277194B2 (en) 2014-06-17 2020-10-22 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016033331A1 (fr) 2014-08-28 2016-03-03 Bioatla, Llc Récepteurs d'antigènes chimères conditionnellement actifs pour cellules t modifiées
WO2016036916A1 (fr) 2014-09-03 2016-03-10 Bioatla, Llc Découverte et production de protéines biologiques conditionnellement actives dans les mêmes cellules hôtes eucaryotes de production
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
EP3265825A4 (fr) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
WO2017015619A1 (fr) 2015-07-23 2017-01-26 The Regents Of The University Of California Anticorps anti-facteur de coagulation xia et leurs utilisations
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
EP3352760B1 (fr) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Polypeptides de liaison à cd3
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
KR102876923B1 (ko) 2015-10-23 2025-10-28 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
EP3368157B1 (fr) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Procédés pour identifier, évaluer, prévenir et traiter des troubles métaboliques au moyen de pm20d1 et d'acides aminés n-lipidés
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
CN116751298A (zh) 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
EP3478325B1 (fr) * 2016-07-01 2024-07-17 Research Development Foundation Élimination de cellules proliférantes de greffons dérivés de cellules souches
EP3515559B1 (fr) 2016-09-20 2025-05-21 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
RU2019127550A (ru) 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
EP3596206A1 (fr) 2017-03-16 2020-01-22 Pfizer Inc Prototrophie à la tyrosine
CA3059938A1 (fr) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complement et leurs conjugues
WO2018200620A1 (fr) 2017-04-25 2018-11-01 National Cheng Kung University Utilisation d'antagonistes de l'il-20 pour le traitement de maladies oculaires
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
EP3634496A4 (fr) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. Procédés de sensibilisation de cellules cancéreuses à une destruction médiée par des lymphocytes t par modulation de voies moléculaires
EP3879535B1 (fr) 2017-06-13 2024-12-11 BostonGene Corporation Systèmes et procédés d'identification de traitements du cancer à partir de scores de biomarqueur normalisés
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
EP3661555B1 (fr) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Anticorps bispécifiques et leurs utilisations
EP3684421A4 (fr) 2017-09-18 2021-08-04 Children's Hospital Medical Center Isolateur fort et ses utilisations dans l'administration de gène
CA3073984A1 (fr) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anticorps anti-ctla4 et utilisations associees
CA3078460A1 (fr) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles et procedes destines a la therapie personnalisee du cancer
EP3688011A4 (fr) 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund Compositions peptidiques et procédés d'utilisation de ces compositions
IL312910B1 (en) 2017-10-27 2026-02-01 Univ New York Anti-galectin-9 antibodies and their uses
KR102769109B1 (ko) 2017-11-24 2025-02-18 유큐(베이징) 바이오파마 코., 엘티디 항―ｏｘ４０ 항체 및 그의 용도
WO2019108777A1 (fr) 2017-11-29 2019-06-06 Research Development Foundation Élimination de cellules proliférantes de greffons dérivés de cellules souches
CA3091352A1 (fr) 2018-02-21 2019-08-29 The University Of Montana Composes de trehalose de diaryle et leurs utilisations
IL276675B2 (en) 2018-02-23 2023-10-01 Eucure Beijing Biopharma Co Ltd Anti-PD-1 antibodies and uses thereof
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
US20210032334A1 (en) 2018-02-28 2021-02-04 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019169313A1 (fr) 2018-03-02 2019-09-06 The University Of Montana Composés de tréhalose immunogènes et leurs utilisations
KR20210007959A (ko) 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
SI3797121T1 (sl) 2018-05-23 2024-09-30 Pfizer Inc. Protitelesa, specifična za CD3, in njihova uporaba
CA3104862A1 (fr) 2018-07-03 2020-01-09 Sotio, LLC Recepteurs chimeriques en association avec des molecules de metabolisme trans ameliorant l'importation de glucose et leurs utilisations therapeutiques
JP7212138B2 (ja) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
KR20210045418A (ko) 2018-08-14 2021-04-26 소티오, 엘엘씨 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도
CA3110837A1 (fr) 2018-08-28 2020-03-05 Vor Biopharma Inc. Cellules souches hematopoietiques genetiquement modifiees et utilisations associees
CA3110006A1 (fr) 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anticorps anti-tnfrsf9 et leurs utilisations
AU2019382505B2 (en) 2018-11-19 2026-02-05 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-PD-1 antibodies and uses thereof
WO2020132190A1 (fr) 2018-12-21 2020-06-25 Multitude Inc. Anticorps spécifiques à muc18
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2020159918A2 (fr) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Anticorps bispécifiques et leurs utilisations
EP3927832A4 (fr) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Animaux non humains génétiquement modifiés ayant un locus d'immunoglobuline humanisée
WO2020223121A1 (fr) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
MX2021014353A (es) 2019-05-23 2022-02-21 The Univ Of Montana Adyuvantes de vacunas basados en ligandos de receptores tlr.
EP3994696B1 (fr) 2019-07-03 2025-05-14 BostonGene Corporation Systèmes et procédés pour la préparation d'échantillons, le séquençage d'échantillons, la correction de biais de données de séquençage et le contrôle de qualité
EP4041308A1 (fr) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulation de vaisseaux lymphatiques dans une maladie neurologique
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
WO2021072244A1 (fr) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anticorps anti-tn et leurs utilisations
US20230075965A1 (en) 2020-01-24 2023-03-09 Constantine S. Mitsiades Uses of biomarkers for improving immunotherapy
EP4093426A1 (fr) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulation de vaisseaux lymphatiques dans une maladie neurologique
WO2021205325A1 (fr) 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
US20230181750A1 (en) 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
US20230235007A1 (en) 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
TW202216779A (zh) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 治療性抗體類和彼等之用途
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
US20230374599A1 (en) 2020-10-19 2023-11-23 Alexander Gusev Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (fr) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Vaccins à cellules de fusion personnalisés
WO2022120256A2 (fr) 2020-12-04 2022-06-09 Bostongene Corporation Techniques d'apprentissage machine hiérarchique permettant d'identifier des catégories moléculaires à partir de données d'expression
WO2022159793A2 (fr) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
WO2022232615A1 (fr) 2021-04-29 2022-11-03 Bostongene Corporation Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
JP2024528139A (ja) 2021-08-02 2024-07-26 ファイザー・インク 改良された発現ベクターおよびその使用
WO2023049933A1 (fr) 2021-09-27 2023-03-30 Sotio Biotech Inc. Polypeptides récepteurs chimériques en combinaison avec des molécules de métabolisme trans qui réorientent des métabolites de glucose hors de la voie de glycolyse et leurs utilisations thérapeutiques
US20250000906A1 (en) 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
EP4473288B1 (fr) 2022-01-31 2025-10-29 BostonGene Corporation Techniques d'apprentissage automatique pour cytométrie
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
WO2023158732A1 (fr) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
EP4555107B1 (fr) 2022-07-15 2026-03-11 BostonGene Corporation Techniques de détection d'une déficience de recombinaison homologue (hrd)
WO2024040207A1 (fr) 2022-08-19 2024-02-22 Sotio Biotech Inc. Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques
US20260053924A1 (en) 2022-08-19 2026-02-26 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024215987A1 (fr) 2023-04-14 2024-10-17 Sotio Biotech Inc. CELLULES IMMUNITAIRES POUR LE TRAITEMENT DU CANCER EN COMBINAISON AVEC DES CONJUGUÉS IL-15/IL-15Rα
WO2025030010A1 (fr) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprenant des cellules souches hématopoïétiques génétiquement modifiées et leurs méthodes d'utilisation
WO2025034542A1 (fr) 2023-08-04 2025-02-13 Cornell University Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie
WO2025096811A1 (fr) 2023-10-31 2025-05-08 Bostongene Corporation Technique d'apprentissage automatique pour identifier des sujets répondant à un inhibiteur de point de contrôle immunitaire (ici) et des sujets n'y répondant pas
WO2025165590A1 (fr) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques de détermination améliorée de charge mutationnelle tumorale (tmb) à l'aide d'une référence génomique spécifique à une population
TW202543672A (zh) 2024-03-27 2025-11-16 丹麥商阿德森多私人有限公司 抗gpc1抗體及其用途
WO2025202359A1 (fr) 2024-03-27 2025-10-02 Adcendo Aps Anticorps anti-gpc1 et leurs utilisations
WO2025223455A1 (fr) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anticorps anti-ptk7/b7h3 et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (fr) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Rétrovirus recombinants
EP0361749A1 (fr) * 1988-09-27 1990-04-04 Dana Farber Cancer Institute Vecteur contenant un provirus de VIH-I compétent pour la réplication et un gène hétérologue
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008450A1 (fr) * 1987-05-01 1988-11-03 Birdwell Finlayson Therapie genetique pour troubles du metabolisme
ATE83008T1 (de) * 1987-07-21 1992-12-15 Du Pont Merck Pharma Verfahren fuer die herstellung von in tierischen zellen stabilen und lebensfaehigen rekombinanten viralen vektoren.
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
JP2917998B2 (ja) * 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
DE68929343T2 (de) * 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (fr) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Rétrovirus recombinants
EP0361749A1 (fr) * 1988-09-27 1990-04-04 Dana Farber Cancer Institute Vecteur contenant un provirus de VIH-I compétent pour la réplication et un gène hétérologue
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell, vol. 53, 8 April 1988, Cell Press, J.M. McCune et al.: "Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus", pages 55-67 *
Nature, vol. 328, 20 August 1987, K. Strebel et al.: "The HIV'A'(sor) gene product is essential for virus infectivity", pages 728-730 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9133524B2 (en) 2010-07-01 2015-09-15 The Regents Of The University Of California Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
US11396551B2 (en) 2018-02-01 2022-07-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
US11987634B2 (en) 2018-02-01 2024-05-21 Pfizer Inc. Antibodies specific for CD70 and their uses
US12152081B2 (en) 2018-02-01 2024-11-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
US12291567B2 (en) 2018-10-15 2025-05-06 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof

Also Published As

Publication number Publication date
AU694685B2 (en) 1998-07-23
EP0487587A1 (fr) 1992-06-03
AU648261B2 (en) 1994-04-21
JP2008029348A (ja) 2008-02-14
EP1001032A2 (fr) 2000-05-17
CA2066053C (fr) 2001-12-11
EP0845537A1 (fr) 1998-06-03
CA2066053A1 (fr) 1991-02-19
JPH04507196A (ja) 1992-12-17
AU5915394A (en) 1994-06-16
WO1991002805A2 (fr) 1991-03-07
EP1645635A2 (fr) 2006-04-12
AU6185390A (en) 1991-04-03
EP1001032A3 (fr) 2005-02-23
EP1645635A3 (fr) 2010-07-07
AU7058496A (en) 1997-01-16
JP4041535B2 (ja) 2008-01-30

Similar Documents

Publication Publication Date Title
WO1991002805A3 (fr) Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
GB9020586D0 (en) Recombinant retroviruses
FI942503A0 (fi) Syövänvastaiset immunoterapeuttiset vektorikonstruktiot
AU4622693A (en) Potentiation of immunogenic response
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
JP2002536417A5 (fr)
ATE270342T1 (de) Endosomolytisch wirksame partikel
FI941474A0 (fi) Seos nukleiinihappo-kompleksien viemiseksi korkeampiin eukaryoottisiin soluihin
RU95105518A (ru) Применение мутантов вируса герпеса, вакцина
ES8500997A1 (es) Un metodo para producir un peptido.
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
DK0835137T3 (da) Indkapslede celler, som danner viruspartikler
WO1994013812A3 (fr) Nouveaux genes de l'entomopoxvirus, nouvelles proteines et leurs procedes d'utilisation
GB1557668A (en) Virus insecticide compositions
EP0327180A3 (fr) Vaccin contenant des polypeptides dérivés du gène de l'enveloppe du virus de l'immunodéficience humaine de type I
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
CA2210294A1 (fr) Compositions immunogenes contenant des virus pox attenues exprimant des antigenes de htlv
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990912590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2066053

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1990912590

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990912590

Country of ref document: EP